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INTRODUCTION 
More than 400 species of microorganisms dwell in the human gastrointestinal tract.1,2 Balance 
between them is vital for the host’s health. Present-day high usage of antibiotics, together with 
environmental and physiological factors, can alter this ecosystem. This imbalance can cause 
illnesses such as diarrhea, which was responsible for 1.31 million deaths in 2015, including 
499,000 among children under five.3,4 Some research has shown that use of probiotics can con-
fer some health benefits, such as treatment for diarrheal disease, prevention of systemic infec-
tions and other effects.2,5 
The 2001 definition from the World Health Organization (WHO) states that probiotics are 
“live microorganisms which, when administered in adequate amounts, confer a health benefit 
on the host”.6 They are currently presented by media sources as an attractive health promotion 
method that prevents or cures a range of clinical situations.7 Indeed, many trials assessing the 
effects of probiotics (including using different species of microorganisms) as preventive or thera-
peutic options for a range of diseases have been conducted and published.2,5 Consequently, a con-
siderable amount of published data is currently available through MEDLINE. Corroborating this, 
a search in this database carried out on July 26, 2017, using the MeSH (medical subheading) term 
probiotics, retrieved 12,370 records, which corresponded to an increase of 278% in the number 
of records over the last ten years (from December 2007 to July 2017). 
The questions that therefore arise are: Should probiotics be indicated for preventive pur-
poses? And if so, for which patients? Which types of probiotics should be used, and at what dose 
and for how long? 
In this review, we identified and summarized all Cochrane systematic reviews about the pre-
ventive effects of probiotics in clinical practice.
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ABSTRACT
BACKGROUND: Probiotics have been used for a range of clinical situations and their use is strongly en-
couraged by the media worldwide. This study identified and summarized all Cochrane systematic reviews 
about the preventive effects of probiotics in clinical practice. 
DESIGN AND SETTING: Review of systematic reviews, conducted in the Discipline of Evidence-Based 
Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (Unifesp). 
METHODS: We included all Cochrane reviews on any probiotics when they were used as preventive in-
terventions and compared with no intervention, placebo or any other pharmacological or non-pharma-
cological intervention. 
RESULTS: 17 Cochrane systematic reviews fulfilled our inclusion criteria and were summarized in this re-
port. None of the reviews included in the present study provided high-quality evidence for any outcome. 
The benefits from use of probiotics included decreased incidence of antibiotic-associated diarrhea and 
Clostridium difficile-associated diarrhea; decreased incidence of upper respiratory tract infections and du-
ration of episodes; decreased need for antibiotics and absences from school due to colds; and decreased 
incidence of ventilator-associated pneumonia. Probiotics seem to decrease the incidence of gestational 
diabetes mellitus, birthweight, risk of vaginal infection and incidence of eczema. 
CONCLUSION: Despite the marketing and the benefits associated with probiotics, there is little scientific 
evidence supporting the use of probiotics. None of the reviews provided any high-quality evidence for 
prevention of illnesses through use of probiotics. More trials are needed to gain better knowledge of pro-
biotics and to confirm when their use is beneficial and cost-effective.
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OBJECTIVE
To summarize the evidence from Cochrane systematic 
reviews focusing on probiotics for prevention of any disease 
or condition.
METHODS 
Design 
Review of Cochrane systematic reviews.
Setting
Discipline of Evidence-Based Medicine of Escola Paulista de 
Medicina (EPM), Universidade Federal de São Paulo (UNIFESP). 
Criteria for including reviews 
• Types of studies 
 We only included the latest version of completed Cochrane 
systematic reviews (SR). We excluded any published protocols 
or any SR marked as “withdrawn” in the Cochrane Database 
of Systematic Reviews (CDSR). 
• Types of participants
 We included healthy participants or those diagnosed with any 
clinical condition or disease.
• Types of intervention
 This review included any probiotics that were used as preven-
tive interventions and compared with no intervention, pla-
cebo or any other pharmacological or non-pharmacological 
intervention.
• Type of outcomes 
 We considered any clinical, social and laboratory outcomes, 
as evaluated in the systematic reviews that were included.
Search for reviews 
We carried out a sensitive systematic search in the Cochrane 
Database of Systematic Reviews (via Wiley) on July 1, 2017. 
The search strategy is presented in Table 1. 
Selection of systematic reviews 
Two of the three researchers (VLB, LPDSR and DDB) indepen-
dently and randomly selected and evaluated all references that 
were retrieved through the systematic search, to confirm their 
eligibility in accordance with the inclusion criteria. Any dis-
agreements were resolved by consulting a more experienced 
author (RR).
Presentation of the results
We presented all the reviews included in this synthesis in a nar-
rative manner (qualitative synthesis). The key points considered 
were their relevance, methods, results, quality of the body of the 
evidence for each outcome, and applicability. 
RESULTS 
Search results
The initial search resulted in 39 reviews and 13 protocols. 
First,  we  excluded all protocols. After full-text assessment, 
we excluded 23 reviews since they either considered use of probi-
otics to be therapeutic interventions rather than preventive inter-
ventions or did not analyze probiotics alone. Thus, 16 Cochrane 
systematic reviews fulfilled our inclusion criteria and were sum-
marized in this report. 
Results from systematic reviews
Among the 16 systematic reviews included, a range of probi-
otic strains was used. Four systematic reviews tested their use 
only among adults,8-11 three only among children12-14 and five 
among both adults and children,15-19 while another four stud-
ies did not specify the age range of the population evaluated.20-23 
Two systematic reviews addressed prevention of respiratory dis-
eases,11,15 nine addressed prevention of gastroenterological dis-
eases,9,10,13,14,16-18,20,21 three addressed gynecological and obstet-
ric diseases,8,22,23 one addressed urological diseases19 and one 
addressed immunological/allergic diseases.12 A summary of 
the reviews included is presented below. The main findings for 
each comparison and the quality of the evidence (based on the 
GRADE approach) are presented in Table 2.8-23
#1 “Probiotics” OR “Probiotic” OR “lactobacillus” OR “lactobacilus” OR 
“lactobacilli” OR “lactobacili” OR “betabacterium” OR “lactobacileae” OR 
“lactobacilleae” OR “lactobacteria” OR “Lactobacillus acidophilus” OR 
“Lactobacilus acidophilus” OR “Lactobacillus casei” OR “Lactobacilus casei” OR 
“Lactobacillus delbrueckii” OR “Lactobacilus delbrueckii” OR “Lactobacillus 
fermentum” OR “Lactobacilus fermentum” OR “Lactobacillus helveticus” OR 
“Lactobacilus helveticus” OR “Lactobacillus leichmannii” OR “Lactobacilus 
leichmannii” OR “Lactobacillus plantarum” OR “Lactobacilus plantarum” OR 
“Lactobacillus reuteri” OR “Lactobacilus reuteri” OR “Lactobacillus rhamnosus” 
OR “Lactobacilus rhamnosus” OR “bifidobacterium” OR “lactococcus” OR 
“streptococcus thermophilus” OR “saccharomyces” OR “bifidobacterium” 
OR “bacillus subtilis” OR “bacillus licheniformis” OR “bugarian bacillus” OR 
“enterococcus faecalis” (Probiotics) OR (Probiotic) OR (lactobacillus) OR 
(lactobacilus) OR (lactobacilli) OR (lactobacili) OR (betabacterium) OR 
(lactobacileae) OR (lactobacilleae) OR (lactobacteria) OR (Lactobacillus 
acidophilus) OR (Lactobacilus acidophilus) OR (Lactobacillus casei) OR 
(Lactobacilus casei) OR (Lactobacillus delbrueckii) OR (Lactobacilus 
delbrueckii) OR (Lactobacillus fermentum) OR (Lactobacilus fermentum) 
OR (Lactobacillus helveticus) OR (Lactobacilus helveticus) OR (Lactobacillus 
leichmannii) OR (Lactobacilus leichmannii) OR (Lactobacillus plantarum) 
OR (Lactobacilus plantarum) OR (Lactobacillus reuteri) OR (Lactobacilus 
reuteri) OR (Lactobacillus rhamnosus) OR (Lactobacilus rhamnosus) OR 
(bifidobacterium) OR (lactococcus) OR (streptococcus thermophilus) OR 
(saccharomyces) OR (bifidobacterium) OR (bacillus subtilis) OR (bacillus 
licheniformis) OR (bugarian bacillus) OR (enterococcus faecalis) in Title, 
Abstract, Keywords
#2 #1 in Cochrane Reviews (complete)
Table 1. Search strategy (July 1, 2017)
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Moderate quality of evidence
Antibiotic-associated diarrhea among children  
The review13 assessed the efficacy and safety of probiotics for pre-
vention of antibiotic-associated diarrhea (AAD) among chil-
dren and included 23 RCTs (938 children, aged 0 to 18 years) 
that compared different types of probiotics versus active treat-
ment, placebo or no treatment. The incidence of antibiotic-asso-
ciated diarrhea was lower in the probiotic group (relative risk, 
RR 0.46; 95% CI 0.35 to 0.61; number needed to treat [NNT] 
10; 22 RCTs; 3,898  participants; I2 = 55%; moderate quality of 
evidence). No adverse events attributable to the treatment were 
found (2455 participants; 16 RCTs) and there was no difference 
between probiotics and controls regarding the risk of adverse 
events for the overall population (risk difference [RD] 0.00; 95% 
CI -0.01 to 0.01; 16 RCTs; 2455 participants). The authors con-
cluded that there was moderate quality of evidence that probiot-
ics seemed to prevent AAD. However, in some groups of patients 
such as immunocompromised individuals and others, serious 
events have been observed, and therefore probiotics should be 
avoided in these groups. For further details, and to check the pro-
biotics used in each study, refer to the original abstract, avail-
able at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD004827.pub4/full.
Clostridium difficile-associated diarrhea 
The review17 evaluated the efficacy and safety of probiotics for 
prevention of Clostridium difficile-associated diarrhea (CDAD) 
and included 31 RCTs (4,492 adults and children), with compari-
sons between probiotics and placebo or no treatment. Probiotics 
presented benefits for reducing the incidence of CDAD (risk ratio 
[RR] 0.36; 95% CI 0.26 to 0.51; 23 RCTs; 4,213 participants, mod-
erate quality of evidence) and of adverse events (RR 0.80; 95% 
CI 0.68 to 0.95; 26 RCTs; 3,964 participants; moderate quality of 
evidence). There was no statistical difference between the groups 
regarding the incidence of C. difficile infection (RR 0.89; 95% CI 
0.64 to 1.24; 13 RCTs; 961 participants; moderate quality of evi-
dence). The authors concluded that, based on the moderate qual-
ity of evidence, use of probiotics seemed to be associated with 
reduction of CDAD and its adverse events. For further details, 
and to check the form of probiotics used in each study, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD006095.pub3/full.
Very low to low quality of evidence
Acute upper respiratory tract infections 
The review15 evaluated the effectiveness and safety of probiot-
ics for prevention of acute upper respiratory tract infections 
(URTIs) and included 13 RCTs (3,780 participants) that com-
pared probiotics with placebo. Probiotics presented benefits 
through reducing the following outcomes:
• the number of people who had one or more URTIs (odds ratio, 
OR 0.53; 95% confidence interval, CI 0.37 to 0.76; 7 RCTs; 
1,927 participants; low quality of evidence);
• the number of people who had three or more URTIs (OR 0.53; 
95% CI 0.36 to 0.80; three RCTs; 650 participants; low quality 
of evidence); 
• the duration of the event (mean difference [MD] -1.89; 
95% CI -2.03 to -1.75; 3 RCTs; 831 participants; low quality 
of evidence);
• the need for antibiotics (OR 0.65; 95% CI 0.45 to 0.94; 4 RCTs; 
1,184 participants; moderate quality of evidence); and 
• missing school due to colds (OR 0.10; 95% CI 0.02 to 0.47; 
1 RCT; 80 children; very low quality of evidence). 
No difference between the groups was found regarding adverse 
events (OR 0.88; 95% CI 0.65 to 1.19; 4 RCTs; 1,234 participants; 
low quality of evidence). The authors concluded that, based on very 
low to low quality of evidence due to the heterogeneity between 
studies, use of probiotics may be associated with reductions in the 
numbers of URTIs, duration of the event, need for antibiotics and 
missing school due to URTIs. For further details, and to check the 
form of probiotics used in each study, refer to the original abstract, 
available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD006895.pub3/full.
Bacterial sepsis and wound 
complications after liver transplantation
The review16 assessed the effects of different interventions for 
prevention of bacterial sepsis and wound complications in 
patients undergoing liver transplantation. Seven RCTs were 
included in this review, but only two (161 participants) assessed 
preventive effects of probiotics. There was no difference between 
probiotics plus prebiotics and selective bowel decontamination 
regarding the risk of needing retransplantation (OR 2.91; 95% 
CI 0.12 to 68.81; 1 RCT; 63 participants) or the risk of graft 
rejection requiring medical treatment (OR 1.94; 95% CI 0.38 
to 9.83; 1 RCT; 63 participants). In comparing probiotics plus 
prebiotics with prebiotics, there was no difference regarding the 
risk of retransplantation (OR 0.33; 95% CI 0.01 to 7.90; 2 RCTs; 
129 participants) or the risk of graft rejection requiring medi-
cal treatment (OR 0.69; 95% CI 0.12 to 3.84; 1 RCT; 63 partici-
pants). The authors’ conclusion was that there was no evidence 
to support use of probiotics for reducing wound complications 
and bacterial sepsis in patients with previous liver transplan-
tation. For further details, and to check the probiotics used in 
each study, refer to the original abstract, available at: http://
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Population and aim Comparison Benefits and harm of probiotics
Quality of 
evidence (GRADE 
approach)
Pediatric patients receiving 
antibiotics13
Probiotics versus placebo
Benefits: decreased incidence of antibiotic-associated diarrhea
ModerateRisk of some adverse effects in immunocompromised, severely 
debilitated and other patients
Adults and children receiving 
antibiotics17
Probiotics versus placebo or 
no treatment
Benefit: decreased incidence of adverse events relating to 
Clostridium difficile-associated diarrhea Moderate
No benefit regarding incidence of Clostridium difficile infection
Adults, children and the 
elderly15
Probiotics versus placebo
Benefit: decreased incidence of upper respiratory tract infections, 
duration of episodes, need for antibiotics and missing school 
due to colds
Very low to low
No difference in adverse events
Patients undergoing liver 
transplantation16
Prebiotics alone or plus 
probiotics versus selective 
bowel decontamination; 
Prebiotics plus probiotics 
versus prebiotics
Benefits: prebiotics plus probiotics decreased the proportion 
of participants with infections and the number of 
infectious episodes Very low
No benefit regarding mortality, need for retransplantation, graft 
rejection, intensive care unit stay or hospital stay
Patients after liver resection9
Probiotics alone or plus 
prebiotics versus placebo 
or prebiotics plus probiotics 
postoperatively 
No benefit regarding mortality Low
Patients with quiescent 
ulcerative colitis20
Probiotics versus placebo 
or mesalazine
No benefit regarding prevention of relapses and adverse events Low
Patients undergoing ileal 
pouch-anal anastomosis for 
chronic ulcerative colitis10
Probiotics versus placebo or 
other treatment
No benefit regarding prevention of pouchitis. Very low
Patients susceptible to 
urinary tract infection and 
healthy people19 
Probiotic versus placebo; 
probiotics versus antibiotics; 
probiotic versus no treatment
No benefit regarding symptomatic bacterial urinary 
tract infection
Low
Patients receiving mechanical 
ventilation11
Probiotics versus placebo
Benefit: decreased incidence of ventilator-associated pneumonia 
Very low to low
No effects regarding intensive care unit mortality, in-hospital 
mortality, incidence of diarrhea, length of intensive care unit stay, 
duration of mechanical ventilation or antibiotic use
Women with HIV-infection for 
prevention of vulvovaginal 
candidiasis23
Probiotics versus placebo or 
clotrimazole
No benefit regarding prevention of vulvovaginal 
candidiasis infection
Low
Infants with family 
history of allergy or food 
hypersensitivity and healthy 
infants12
Probiotics alone or plus 
prebiotics versus placebo
Benefit: decreased incidence of infant eczema
Not assessedNo benefit regarding food hypersensitivity, asthma, atopic 
eczema, allergic rhinitis, food allergy or urticaria
Pregnant women without 
metabolic or chronic 
diseases8
Probiotics versus placebo 
or diet
Benefit: probiotics decreased both the rate of gestational 
diabetes mellitus and the birthweight
Not assessedNo benefit regarding death (abortion, intrauterine fetal death, 
stillbirth or neonatal death), risk of premature birth or cesarean 
delivery rate
Patients with Crohn’s 
disease18
Probiotics versus placebo or 
other treatment
No benefit regarding reduction of the risk of relapse 
after surgically-induced remission, compared with use of 
aminosalicylates or azathioprine.
Not assessed
Risk of some adverse effects from Lactobacillus GG
Infants born at gestational 
age of less than 37 weeks or 
weighing less than 2500 g at 
birth, or both14
Probiotics versus placebo or 
no treatment
Benefit: decreased incidence of severe necrotizing enterocolitis 
and mortality among preterm infants
Not assessed
No effect regarding nosocomial sepsis
Patients undergoing surgery 
related to Crohn’s disease21 
Probiotics versus placebo
No benefit regarding clinical recurrence, severe endoscopic 
recurrence or any endoscopic recurrence
Not assessed
Pregnant women22
Probiotics versus placebo or 
acetic acid
Benefit: decreased risk of vaginal infection 
Not assessed
No effect regarding prevention of preterm birth
Table 2. Characteristics, main findings and quality of evidence from systematic reviews focusing on patient-directed interventions 
with probiotics
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Infections after liver resection 
The review9 assessed the benefits and harm of different interven-
tions for prevention of infectious complications and improving 
the outcomes after liver resection. Seven RCTs were included, 
but only two RCTs (125 participants) evaluated probiotics as pre-
ventive interventions. One of these compared use of prebiotics 
and probiotics versus placebo and found that there was no dif-
ference in mortality (RR 0.36; 95% CI 0.10 to 1.35; 44  partici-
pants). The other RCT, with 81 participants, compared use of pre-
operative and postoperative prebiotics and probiotics versus use 
of postoperative prebiotics and probiotics and found that there 
was no significant difference in mortality (RR 0.39; 95% CI 0.15 
to 1.00). Both of these studies presented low quality of evidence.
The authors’ conclusion was that there was no evidence to 
support or refute the use of any type of treatment to decrease 
the frequency of infectious complications after liver resection. 
For further information, refer to: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD006933.pub2/full.
Maintenance of remission in ulcerative colitis
The review20 assessed the efficacy and safety of probiotics for 
prevention of relapses in cases of ulcerative colitis. Four RCTs 
(587 participants) were included and these showed the follow-
ing: probiotics versus mesalazine: no difference between the 
groups regarding the risk of relapse (OR 1.33; 95% CI 0.94 to 
1.90; 3 RCTs; 555 participants; low quality of evidence) or the 
incidence of adverse events (OR 1.21; 95% CI 0.80 to 1.84; 2 
RCTs; 430 participants; moderate quality of evidence); probi-
otics versus placebo: no difference between the groups regard-
ing the risk of relapse (OR 0.27; 95% CI 0.03 to 2.68; 1 RCT; 32 
participants; moderate quality of evidence). The authors con-
cluded that there was insufficient evidence to support use of 
probiotics for preventing relapses in cases of ulcerative colitis. 
For further details, and to check the form of probiotics used 
in each study, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD007443.
pub2/full.
Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis 
The review10 assessed the effectiveness of different interventions 
for prevention of pouchitis after ileal pouch-anal anastomosis in 
cases of chronic ulcerative colitis. Thirteen RCTs were included 
in this review, but only two studies were about the use of pro-
biotics. One RCT assessed prevention of pouchitis in patients 
with ileal pouch-anal anastomosis and showed that there were no 
benefits from using Bifidobacterium longum, in comparison with 
placebo (RR 1.43; 95% CI 0.66 to 3.11; 1 RCT; 12 participants; 
very low quality of evidence).
Another outcome assessed related to treatment of acute pouchi-
tis. One RCT with 20 participants compared the use of Lactobacillus 
GG with placebo and there was no difference in clinical improve-
ment (RR 3.95%; CI 0.14 to 65.9), with very low quality of evidence.
The authors’ conclusions, based on the very low quality of 
evidence, was that probiotics did not seem to prevent pouchitis 
after ileal pouch-anal anastomosis in cases of chronic ulcerative 
colitis or to have any effect in treatments for patients with acute 
pouchitis. For more information about the other types of treat-
ment in this study, refer to this link: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD001176.pub3/full.
Urinary tract infections 
The review19 evaluated the effects of probiotics for prevention 
of urinary tract infections in susceptible or healthy adults and 
children. Nine RCTs (735 participants) were included and these 
showed that there was no difference in the risk of symptomatic 
bacterial urinary tract infection, in comparisons of use of pro-
biotics versus placebo (OR 0.82; 95% CI 0.60 to 1.12; 6 RCTs; 
352 participants) or use of probiotics versus antibiotics (OR 1.12; 
95% CI 0.95 to 1.33; 1 RCT; 158 women).
The authors concluded that, based on the few studies avail-
able, which were of small size (low quality of evidence), there 
was no benefit from using probiotics, in comparison with pla-
cebo or no treatment. For further details, and to check the pro-
biotics used in each study, refer to the original abstract, avail-
able at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD008772.pub2/full.
Ventilator-associated pneumonia 
The review11 assessed the effects of probiotics for prevention of 
ventilator-associated pneumonia (VAP). Eight randomized clin-
ical trials (RCTs) (1,083 adults) that compared use of probiot-
ics with placebo, usual care and multiple treatment arms were 
included. Probiotics were shown to present some benefit regard-
ing reduction of the incidence of VAP (odds ratio, OR 0.70; 95% 
CI 0.52 to 0.95; 8 RCTs; 1,018 participants; low quality evidence). 
No difference was found between the probiotics and control 
groups in relation to the following outcomes,:
• intensive care unit (ICU) mortality (OR 0.84; 95% CI 0.58 to 
1.22; 5 RCTs; 703 participants; very low quality of evidence);
• in-hospital mortality (OR 0.78; 95% CI 0.54 to 1.14; 4 RCTs; 
524 participants; very low quality of evidence); 
• incidence of diarrhea (OR 0.72; 95% CI 0.47 to 1.09; 4 RCTs; 
618 participants; low quality of evidence);
• length of ICU stay (mean difference, MD -1.60; 95% CI -6.53 
to 3.33; 4 RCTs; 396 participants; very low quality of evidence); 
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• duration of mechanical ventilation (MD -6.15; 95% CI -18.77 
to 6.47; 2 RCTs; 203 participants; very low quality of evidence); 
and
• antibiotic use (OR 1.23; 95% CI 0.51 to 2.96; 1 RCT; 259 par-
ticipants; low quality of evidence). 
The authors concluded that, based on the low quality of 
evidence, use of probiotics may be associated with reduction 
in VAP. For further details, and to check the probiotics used 
in each study, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD011513.
pub2/abstract.
Vulvovaginal candidiasis in HIV-infected women
The review23 aimed to assess the effects of many antifungals 
that are administered vaginally or orally, including probiotics, 
for treatment and prevention of vulvovaginal candidiasis (VVC) 
in HIV-infected women. Two trials (431 participants) on use of 
probiotics as preventive interventions were included. No differ-
ence regarding this outcome was found in comparisons of probi-
otics versus clotrimazole (RR 1.11; 95% CI 0.45 to 2.76; low qual-
ity of evidence) or versus placebo (RR 0.54; 95% CI 0.26 to 1.13; 
low quality of evidence). The authors’ conclusion was that no 
implications for practice could be determined. For other results 
from this review, refer to this link: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD008739.pub2/full.
Quality of evidence not assessed 
Allergic disease and food hypersensitivity among children 
The review12 assessed the effect of probiotics for prevention 
of allergic disease relating to food hypersensitivity among 
infants. It included 12 RCTs that compared use of probiot-
ics with placebo or use of probiotics plus prebiotics with pla-
cebo. The overall results from the pooled data showed that 
the incidence of infant eczema was reduced in the probiot-
ics group (RR 0.82; 95% CI 0.70 to 0.95; 5 RCTs; 1,477 par-
ticipants; I2 = 63.6%). However, these studies were hetero-
geneous and there was no statistical difference when the 
analysis was limited to atopic eczema (RR 0.80; 95% CI 0.62 
to 1.02). There was also no significant difference regarding 
the other outcomes evaluated. The authors concluded that 
there was insufficient evidence to support use of probiot-
ics for preventing allergies or food hypersensitivity among 
infants, given that the findings were inconsistent and there 
were many follow-up losses. For further details, and to check 
the form of probiotics used in each study, refer to the orig-
inal abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD006475.pub2/full.
Gestational diabetes in women 
without metabolic or chronic diseases
The review8 evaluated the effects of probiotics for prevention of 
gestational diabetes mellitus (GDM). One RCT (256 pregnant 
women) was included and it found that there were benefits from 
use of probiotics (compared with placebo or diet) for reducing the 
rate of GDM (RR 0.38; 95% CI 0.20 to 0.70; 225 women) and for 
reducing the birthweight (MD -127.71 g; 95% CI -251.37 to -4.06; 
256 women). No difference between the groups was found for the 
following outcomes:
• death (OR 2.00; 95% CI 0.35 to 11.35; 256 women); 
• risk of premature birth (RR 3.27; 95% CI 0.44 to 24.43; 
238 women); 
• cesarean delivery (RR 1.23; 95% CI 0.65 to 2.32; 218 women). 
All the infants included in this study were within the normal 
range for birthweight. The authors concluded that use of probi-
otics seemed to be associated with reduction in GDM. However, 
they considered that further studies would be required to confirm 
these results. For more details, and to check the form of probiot-
ics used in each study, refer to the original abstract, available at: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009951.
pub2/full.
Maintenance of remission of Crohn’s disease 
The review18 assessed the effectiveness of probiotics for mainte-
nance of remission in cases of Crohn’s disease. Seven RCTs, com-
paring use of probiotics versus placebo, were included. In evalu-
ating the risk of relapse among adults, there were no differences 
between the following:
• E. coli Nissle and placebo (RR 0.43; 95% CI 0.15 to 1.20; 1 RCT; 
20 participants); 
• Lactobacillus GG and placebo after surgically-induced remis-
sion (RR 1.58; 95% CI 0.30 to 8.4; 1 RCT; 37 participants) or 
medically-induced remission (RR 0.83; 95% CI 0.25 to 2.80; 
1 RCT; 9 participants); 
• Lactobacillus GG and maintenance therapy with aminosalic-
ylates or azathioprine (RR 0.67; 95% CI 0.13 to 3.30; 1 RCT; 
24 participants). 
Regarding the risk of relapse among children, there was no 
difference between Lactobacillus GG and placebo (RR 1.85; 95% 
CI 0.77 to 4.40; 1 RCT; 75 participants).
Regarding the risk of adverse events, Lactobacillus GG was 
associated with a risk of adverse events in comparison with 
maintenance therapy using aminosalicylates or azathioprine (no 
numerical data provided). A small RCT found that, at the end 
of the study, there was no difference in use of Saccharomyces 
boulardii plus conventional maintenance therapy versus placebo 
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plus conventional maintenance therapy for relapses, according 
to the clinical disease activity index (CDAI) (RR 0.17; 95% CI 
0.02 to 1.23).  
The authors concluded that there was no evidence that probiot-
ics were beneficial for maintenance of remission in cases of Crohn’s 
disease. For further details, and to check the probiotics used in each 
study, refer to the original abstract, available at: http://onlinelibrary.
wiley.com/doi/10.1002/14651858.CD004826.pub2/full. 
Necrotizing enterocolitis in premature newborns
The review14 assessed the efficacy and safety of probiotics for 
prevention of severe necrotizing enterocolitis (NEC) or sep-
sis in premature infants. Twenty-four RCTs, comparing use 
of probiotics with placebo or no treatment, were included. 
Probiotics showed some benefit regarding reduction of the inci-
dence of severe NEC (RR 0.43; 95% CI 0.33 to 0.56; 20 RCTs; 
5,529 infants) and all-cause mortality (RR 0.65; 95% CI 0.52 to 
0.81; 17 RCTs; 5,112 infants). Comparison between use of pro-
biotics and placebo or no treatment showed that there was no 
statistical difference in the incidence of nosocomial sepsis (RR 
0.91; 95% CI 0.80 to 1.03; 19 RCTs; 5,338 infants). The authors 
concluded that use of enteral probiotics seemed to be associated 
with reduction of severe NEC and mortality among premature 
infants. For further details, and to check the form of probiot-
ics used in each study, refer to the original abstract, available 
at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD005496.pub4/full.
Postoperative recurrence of Crohn’s disease 
The objective of the review21 was to evaluate the medical thera-
pies for prevention of postoperative recurrence of Crohn’s dis-
ease. It included 23 RCTs, but only 4 RCTs were about probi-
otics. These RCTs found that there was no difference between 
probiotics and placebo regarding the risk of clinical recur-
rence (RR 1.41; 95% CI 0.59 to 3.36; 3 RCTs; 213 adults), risk 
of severe endoscopic recurrence (RR 0.96; 95% CI 0.58 to 1.59; 
four RCTs; 333 adults) or risk of any endoscopic recurrence (RR 
0.98; 95% CI 0.74 to 1.29; 3 RCTs; 213 adults). The authors con-
cluded that there was no difference in effect between use of pro-
biotics and placebo. For information on the other medical thera-
pies included in this review, refer to this link: http://onlinelibrary.
wiley.com/doi/10.1002/14651858.CD006873.pub2/full.
Preterm labor
The review22 assessed the effectiveness and safety of probiotics 
for prevention of premature labor and delivery and included 
three RCTs (344 pregnant women) that compared use of pro-
biotics with acid acetic and placebo. The following results were 
found: use of probiotics reduced the risk of vaginal infection 
in comparison with the controls (acetic acid or placebo) (RR 
0.19; 95% CI 0.08 to 0.48; 88 pregnant women); comparison of 
use of probiotics plus dietary counselling versus control (pla-
cebo plus dietary counselling or placebo only) showed that there 
was no difference between the groups regarding birth at gesta-
tional ages of less than 32 weeks (RR 0.65; 95% CI 0.03 to 15.88; 
1 RCT; 238 pregnant women) or birth between the gestational 
ages of 32 and 37 weeks (RR 3.95; 95% CI 0.36 to 42.91; 1 RCT; 
238 pregnant women). 
The authors concluded that use of probiotics seemed to be 
associated with lower risk of vaginal infection during pregnancy 
and that there was insufficient evidence to support their use for 
prevention of premature birth. For further details, and to check the 
form of probiotics used in each study, refer to the original abstract, 
available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD005941.pub2/full.
DISCUSSION
This overview found that despite increasing marketing of probi-
otics, there are still few systematic reviews on the preventive use 
of probiotics and there is a scarcity of high-quality randomized 
trials. None of the reviews included in the present study provided 
high-quality evidence for any outcome.
Many clinical trials assessed in this study showed very low or 
low quality of evidence. Another point that needs to be noted is 
the huge variety of probiotics that have been considered in RCTs. 
This made it difficult to identify the individual effect of each pro-
biotic agent, and also precluded meta-analyses.
Most of the studies focused on gastrointestinal diseases. 
We found that there were some benefits from use of probiot-
ics, with moderate quality of evidence, regarding their use for 
decreasing the incidence of antibiotic-associated diarrhea among 
children13 and the incidence of Clostridium difficile-associated 
diarrhea among adults and children.17 Other benefits that were 
observed with very low or low quality of evidence were that use 
of probiotics decreased the incidence of infections and the num-
ber of infectious episodes in patients undergoing liver trans-
plantation.16 The benefit of decreased incidence of severe nec-
rotizing enterocolitis and mortality among preterm infants was 
noted in another review, but the quality of its evidence could 
not be assessed.14
In relation to respiratory diseases, probiotics showed some 
benefits regarding decreased incidence of upper respiratory 
tract infections and duration of episodes, the need for antibi-
otics and missing school due to colds,15 and regarding the inci-
dence of ventilator-associated pneumonia in patients receiv-
ing mechanical ventilation.11 These studies were classified 
as presenting very low or low quality of evidence, using the 
GRADE approach. 
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In three systematic reviews about gynecological and 
obstetric diseases, we found that there were some bene-
fits in relation to decreasing the rate of gestational diabetes 
mellitus, decreasing both the birthweight8 and the risk of 
vaginal infection,22 although the quality of evidence could 
not be assessed. One RCT found that there was a benefit in 
relation to reducing the incidence of eczema among infants 
with a family history of allergy or food hypersensitivity and 
among healthy infants.12 
Despite the potential benefits of probiotics, we did not find any 
high-quality evidence that could change clinical practice or recom-
mendations for their use. Furthermore, some probiotics may be 
harmful in groups of patients such as those presenting immuno-
suppression, severe debilitation and other such conditions. On the 
other hand, it is important to examine the number needed to treat 
(NNT) and to analyze the cost-effectiveness of use of probiotics. 
Goldenberg et al. concluded that the NNT to prevent one case of 
diarrhea was ten. Thus, in this example, probiotics reduced the 
number of cases of diarrhea even with only a few patients treated.13 
To prevent Clostridium difficile-associated diarrhea, 29 patients 
would need to be treated.17   
Our systematic review has the advantage of the number of 
studies included, given that the topic of probiotics is currently a 
matter of debate and that there are uncertainties regarding their 
effectiveness. Another advantage is that it summarizes the evidence 
relating to probiotics and their use that has been gathered in the 
Cochrane Library, which is recognized as the largest database of 
systematic reviews, given that the information about probiotics is 
distributed among many studies.
This overview has some limitations. Our search was con-
ducted in a single database, even though the Cochrane Library 
is recognized as the most important database of systematic 
reviews. The limited data available is a consequence of the 
small number of papers, and the low quality of evidence is 
related to the small sample sizes and bias of the RCTs. Another 
point that should be noted is the huge variety of prebiotics 
that have been considered in RCTs, which led to difficulty in 
identifying the individual effect of each probiotic agent, and 
also precluded meta-analyses. The NNT was not determined 
in some reviews, which made it more challenging to analyze 
cost-effectiveness.
Regarding the implications for practice, our study summa-
rizes the use of probiotics as a preventive intervention for some 
clinical settings and shows the situations in which there is a real 
benefit. From this, healthcare professionals can decide when to 
indicate probiotics for patients and can improve outcomes in 
their hospitals. For example, probiotics can be used to reduce the 
incidence of vaginal infection during pregnancy and to decrease 
the incidence of VAP. On the other hand, probiotics should not 
be recommended when there is uncertainty about their bene-
fits and harm. 
Here, we make it clear that much needs to be done in rela-
tion to studying probiotics. Firstly, basic research is needed in 
order to elucidate the pathophysiological links between different 
diseases and use of probiotics. Secondly, RCTs with high-quality 
evidence are needed, with larger sample sizes and better con-
trol over variables. Thirdly, research on the cost-effectiveness 
of use of probiotics needs to be stimulated, because their use 
must be analyzed in terms of their consequences for health and 
economic repercussions.
CONCLUSION
This overview included 16 Cochrane systematic reviews 
about the use of probiotics as preventive measures within clin-
ical practice. There was little scientific evidence to support 
the use of probiotics. None of the reviews provided high-qual-
ity evidence for preventive action achieved through use of 
probiotics and each review analyzed only a few randomized 
controlled trials. 
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